CA1075600A - Dosage immunologique de la thymopoietine - Google Patents
Dosage immunologique de la thymopoietineInfo
- Publication number
- CA1075600A CA1075600A CA282,819A CA282819A CA1075600A CA 1075600 A CA1075600 A CA 1075600A CA 282819 A CA282819 A CA 282819A CA 1075600 A CA1075600 A CA 1075600A
- Authority
- CA
- Canada
- Prior art keywords
- thymopoietin
- antibody
- antigen
- labeled
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000898 Thymopoietin Substances 0.000 title claims abstract description 93
- 102100023981 Lamina-associated polypeptide 2, isoform alpha Human genes 0.000 title claims abstract description 81
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 title claims abstract description 81
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 title claims abstract description 81
- 238000003018 immunoassay Methods 0.000 title abstract description 10
- 238000003556 assay Methods 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims description 41
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 9
- 108010074605 gamma-Globulins Proteins 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 230000001588 bifunctional effect Effects 0.000 claims description 8
- 239000003610 charcoal Substances 0.000 claims description 8
- 239000012876 carrier material Substances 0.000 claims description 7
- 125000005647 linker group Chemical group 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 229920002307 Dextran Polymers 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- 238000003127 radioimmunoassay Methods 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 239000004816 latex Substances 0.000 claims description 3
- 229920000126 latex Polymers 0.000 claims description 3
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 claims description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 229940044173 iodine-125 Drugs 0.000 claims description 2
- 229910052722 tritium Inorganic materials 0.000 claims description 2
- 238000004435 EPR spectroscopy Methods 0.000 claims 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 208000002720 Malnutrition Diseases 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 239000013060 biological fluid Substances 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 abstract description 2
- 238000002405 diagnostic procedure Methods 0.000 abstract description 2
- 230000001071 malnutrition Effects 0.000 abstract description 2
- 235000000824 malnutrition Nutrition 0.000 abstract description 2
- 230000001404 mediated effect Effects 0.000 abstract description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 abstract description 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000003669 immune deficiency disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000001538 myasthenic effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000000724 thymus hormone Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 229960002086 dextran Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- -1 e.g. Polymers 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- KYRUKRFVOACELK-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(4-hydroxyphenyl)propanoate Chemical compound C1=CC(O)=CC=C1CCC(=O)ON1C(=O)CCC1=O KYRUKRFVOACELK-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229960001479 tosylchloramide sodium Drugs 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- ZESIQEJMZPNWOD-UHFFFAOYSA-N 2-(4-hydroxyphenyl)propanoic acid;1-hydroxypyrrolidine-2,5-dione Chemical class ON1C(=O)CCC1=O.OC(=O)C(C)C1=CC=C(O)C=C1 ZESIQEJMZPNWOD-UHFFFAOYSA-N 0.000 description 1
- ZHMMPVANGNPCBW-UHFFFAOYSA-N 4-Hydroxyhydratropate Chemical class OC(=O)C(C)C1=CC=C(O)C=C1 ZHMMPVANGNPCBW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 101000638751 Bos taurus Thymopoietin-1 Proteins 0.000 description 1
- 101000753683 Bos taurus Thymopoietin-2 Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241001237728 Precis Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940000986 dextran 110 Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 108010077055 methylated bovine serum albumin Proteins 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002810 primary assay Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/709,565 US4055633A (en) | 1976-07-28 | 1976-07-28 | Immunoassay for thymopoietin |
| US05/810,269 US4124700A (en) | 1976-07-28 | 1977-06-27 | Immunoassay for thymopoietin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1075600A true CA1075600A (fr) | 1980-04-15 |
Family
ID=27108277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA282,819A Expired CA1075600A (fr) | 1976-07-28 | 1977-07-15 | Dosage immunologique de la thymopoietine |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS6012576B2 (fr) |
| AU (1) | AU497627B1 (fr) |
| CA (1) | CA1075600A (fr) |
| DE (1) | DE2733561C3 (fr) |
| FR (1) | FR2359851A1 (fr) |
| GB (1) | GB1545332A (fr) |
| IT (1) | IT1126757B (fr) |
| NZ (1) | NZ184667A (fr) |
| SE (1) | SE447165B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2557458B1 (fr) * | 1983-12-30 | 1987-09-04 | Centre Nat Rech Scient | Nouveaux anticorps capables de reconnaitre specifiquement des groupements hapteniques, leur preparation et leur application, et nouveaux antigenes permettant de les preparer |
| GB2160312B (en) * | 1984-04-13 | 1987-09-16 | South African Inventions | Adjuvant for immunisation |
| FR2581313A1 (fr) * | 1985-05-02 | 1986-11-07 | Pasteur Institut | Composes suscitant la formation d'anticorps, compositions immunogeniques et compositions immunoprotectrices les contenant et procede d'obtention d'anticorps les mettant en oeuvre |
| US5593842A (en) * | 1994-09-20 | 1997-01-14 | Gideon Goldstein | Method of measuring thymopoietin proteins in plasma and serum including acidification of the plasma and serum |
-
1977
- 1977-07-15 CA CA282,819A patent/CA1075600A/fr not_active Expired
- 1977-07-18 NZ NZ18466777A patent/NZ184667A/xx unknown
- 1977-07-19 GB GB3017777A patent/GB1545332A/en not_active Expired
- 1977-07-26 DE DE19772733561 patent/DE2733561C3/de not_active Expired
- 1977-07-26 IT IT5044677A patent/IT1126757B/it active
- 1977-07-27 AU AU27382/77A patent/AU497627B1/en not_active Expired
- 1977-07-27 SE SE7708625A patent/SE447165B/xx not_active IP Right Cessation
- 1977-07-27 FR FR7723092A patent/FR2359851A1/fr active Granted
- 1977-07-27 JP JP9021277A patent/JPS6012576B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IT1126757B (it) | 1986-05-21 |
| GB1545332A (en) | 1979-05-10 |
| SE7708625L (sv) | 1978-01-29 |
| DE2733561C3 (de) | 1980-04-03 |
| FR2359851A1 (fr) | 1978-02-24 |
| JPS6012576B2 (ja) | 1985-04-02 |
| NZ184667A (en) | 1980-02-21 |
| FR2359851B1 (fr) | 1983-04-01 |
| JPS5459318A (en) | 1979-05-12 |
| AU497627B1 (en) | 1978-12-21 |
| DE2733561B2 (de) | 1979-07-26 |
| SE447165B (sv) | 1986-10-27 |
| DE2733561A1 (de) | 1978-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Theofilopoulos et al. | The nature of immune complexes in human cancer sera | |
| CA1225590A (fr) | Utilisation d'anticorps anti-idiotype dans des dosages immunologiques | |
| Kakumu et al. | Occurrence and significance of antibody to liver-specific membrane lipoprotein by double-antibody immunoprecipitation method in sera of patients with acute and chronic liver diseases | |
| US4312853A (en) | Radioimmunological determination of procollagen (type III) and procollagen peptide (type III) | |
| US4514505A (en) | Monoclonal antibody mixtures and use thereof for enhanced sensitivity immunoassays | |
| JPH06317589A (ja) | アッセイ干渉を排除したイムノアッセイ法およびキット | |
| US4124700A (en) | Immunoassay for thymopoietin | |
| JPS6180048A (ja) | 重抗原のための螢光偏光イムノアツセイ | |
| US4264571A (en) | Radioimmunoassay of thymosin α1 | |
| US4489167A (en) | Methods and compositions for cancer detection | |
| Mercham et al. | [42] Antibodies to insoluble and solubilized elastin | |
| Goldstein | Radioimmunoassay for thymopoietin | |
| JP3362054B2 (ja) | 扁平上皮がん状物質およびその分離方法 | |
| FI95579C (fi) | Immunologinen menetelmä intaktin prokollageenipeptidin (tyyppi III) ja prokollageenin (tyyppi III) määrittämiseksi selektiivisesti elimistönesteistä ja väline sen toteuttamiseksi | |
| US5324822A (en) | Method of isolating a CA 195-like immunoreactive antigen from human amniotic fluid | |
| CA1075600A (fr) | Dosage immunologique de la thymopoietine | |
| EP0245052A2 (fr) | Détection d'inflammation et anticorps à cet effet | |
| US4792528A (en) | Methods for obtaining monoclonal antibodies useful in enhanced sensitivity immunoassays | |
| US4096237A (en) | Immunoassay for β-endorphin | |
| Suzuta | Therapeutic and diagnostic applications of latex-bound immunoglobulins | |
| Grassi et al. | Two different approaches for developing immunometric assays of haptens | |
| JPS6212859A (ja) | 特定の細菌ポリペプチド及びそれに対する抗体の定量法 | |
| Kilgallon et al. | Anti-C1q column: ligand specific purification of immune complexes from human serum or plasma. Analysis of the interaction between C1q and immune complexes. | |
| JPH07110879B2 (ja) | モノクロナール抗体 | |
| Goldstein | Immunoassay for thymopoietin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |